What are ADC's

Our services

ADC Review
is made possible by:

NCT00073749 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating CMC-544 In B-Cell Non-Hodgkin’s Lymphoma (NCT00073749)

Trial Description
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 (inotuzumab ozogamycin) in subjects with B-cell Non-Hodgkin’s Lymphoma (NHL).

This trial is sponsored by Pfitzer. [1]

Study Data

  • Condition: B-Cell Lymphoma
  • Interventions:
    • Drugs used in this trial
      • Inotuzumab ozogamicin (CMC-544)
  • Phase: I
  • Enrollment: 80
  • Start: August 2003
  • Completion: December 2010
  • Last verified: February 2013

Study Schematic 


Click here to Return to Drug map

Last Editorial review: July 31, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar